On November 6, Neurology Today Online featured Tisch MSRCNY in a review of news coming out of the ACTRIMS/ECTRIMS Annual Meeting in September examining the safety of stem cell therapy in MS treatment. The article discussed two different trials that were found to be safe and well tolerated in multiple sclerosis patients: one using intravenous injection of mesenchymal stem cells and the other Tisch MSRCNY’s protocol using intrathecal injections of mesenchymal stem cells.
Tisch MS News
Thank you to all who attended the 17th Annual Tisch MS Research Patient Symposium. In response to your requests, a review of the material presented will be posted on this website and appear in the next issue of our newsletter, Healing MS.
Dr. Violaine Harris and Dr. Saud A. Sadiq co-authored a review entitled “Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status and this has been accepted for publication in the Journal Molecular Diagnosis and Therapy.
The journal Neurology® Neuroimmunology and Neuroinflammation accepted a paper by lead author Dr. Fozia Mir entitled, “Cerebrospinal fluid isoprostane levels are a biomarker of oxidative stress in multiple sclerosis.” The paper is authored by Dr. Mir, Donald Lee, Hetal Ray, and Saud A. Sadiq, MD and in it the team has identified a lipid, 8-iso-prostaglandinF2α (8-iso-PGF2α), as a biomarker for disease activity and oxidative stress in the cerebrospinal fluid (CSF) of multiple sclerosis patients.
Last week your Tisch MSRCNY researchers presented six abstracts, including five posters, at the Joint ACTRIMS-ECTRIMS Meeting (Americas and European Committees for Treatment and Research in Multiple Sclerosis) in Boston. This was the sixth triennial event dedicated to advancing the understanding of MS and attracted over 9,000 delegates including more than one hundred exhibitors.
Tisch MS Research Center of New York is proud to be featured in the September 2014 issue of “Neurology Today.” The article “Myelinating Oligodendrocytes Derived from Primary Progressive MS Patients: Scientists Developed Faster, More Efficient Methodology,” discusses research focusing on an accelerated protocol to induce stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system.
Your Tisch MS Researchers head to Boston today to present their work at the 2014 Joint ACTRIMS-ECTRIMS Meeting! We will bring you updates from this important conference discussing the latest research and treatments in MS.
The Tisch Center is excited to announce that a team led by Dr. Massimiliano Cristofanilli has succeeded in a three year effort to create a model of progressive multiple sclerosis. Currently the widely used experimental model of multiple sclerosis known as EAE best mimics relapsing-remitting MS (RRMS).
The Tisch MS Research Center presented two posters at the International Society for Stem Cell Research (ISSCR) 12th Annual Meeting last week based on the following study.
Safety and Dosing of Autologous Neural Progenitors Injected Intrathecally in Multiple Sclerosis Patients: Results of a Pilot Study
Saud A. Sadiq, and Violaine K. Harris
We are pleased to announce, Dr. Saud A. Sadiq, Director of the International Multiple Sclerosis Management Practice (IMSMP) and Tisch MS Research Center of New York (Tisch MSRCNY) has been elected a Fellow Member of the American Academy of Neurology (AAN). This outstanding achievement recognizes the contributions Dr. Sadiq has made to the Academy and to the neurology community. To receive this prestigious honor, accomplishments both academically and clinically were taken into consideration.